GeoVax Labs (NASDAQ:GOVX) versus Mirum Pharmaceuticals (NASDAQ:MIRM) Critical Survey

GeoVax Labs (NASDAQ:GOVX – Get Free Report) and Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Institutional & Insider Ownership

6.1% of GeoVax Labs shares are owned by institutional investors. 0.2% of GeoVax Labs shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares GeoVax Labs and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GeoVax Labs N/A -1,010.68% -420.06%
Mirum Pharmaceuticals -134.75% -97.25% -12.59%

Earnings & Valuation

This table compares GeoVax Labs and Mirum Pharmaceuticals”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GeoVax Labs $2.49 million 0.35 -$21.47 million ($11.34) -0.15
Mirum Pharmaceuticals $670.78 million 9.15 -$23.36 million ($15.47) -6.08

GeoVax Labs has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for GeoVax Labs and Mirum Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeoVax Labs 1 1 1 0 2.00
Mirum Pharmaceuticals 1 0 13 1 2.93

GeoVax Labs presently has a consensus price target of $3,600.00, indicating a potential upside of 210,426.32%. Mirum Pharmaceuticals has a consensus price target of $155.56, indicating a potential upside of 65.51%. Given GeoVax Labs’ higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Mirum Pharmaceuticals.

Volatility and Risk

GeoVax Labs has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.

Summary

Mirum Pharmaceuticals beats GeoVax Labs on 8 of the 15 factors compared between the two stocks.

About GeoVax Labs

(Get Free Report)

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.